HDF-iPSCs
The cell line is not validated yet.
MUSIi009-A
General
Donor Information
General Donor Information |
|
Sex | unknown |
Age of donor (at collection) | fetal |
Phenotype and Disease related information (Donor) |
|
Diseases | No disease was diagnosed.
|
Karyotyping (Donor) |
|
Has the donor karyotype been analysed? |
Yes
|
Other Genotyping (Donor) |
|
Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
BioSamples | SAMEA110691898 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
Please provide contact information of the holder of the original Donor Information Sheet. | We used dermal fibroblasts purchased from ScienCell Research Laboratories (Catalog #2300). |
Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
If you do not hold the Donor Consent Form, do you know who does? | No |
Alternatives to consent are available? | Yes |
Alternatives to consent | Product sheet |
Alternative consent approval number | |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | No |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
How may genetic information associated with the cell line be accessed? | Controlled Access |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | No |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
Source cell line name |
Human dermal fibroblasts Derived from same source line (potentially other lot and donor, see below):
|
Source cell type | |
Source cell origin | |
Source cell type (free text) | Skin Biopsy |
Age of donor (at collection) | fetal |
Source cell line vendor | ScienCell Research Laboratories |
Passage number reprogrammed | 6 |
Reprogramming method |
|
Vector type | Integrating |
Vector | Virus (Retrovirus) |
Is the used vector excisable? |
Unknown |
Absence of reprogramming vector(s)? |
Unknown |
Reprogramming vectors silenced? | |
Vector free reprogramming |
|
Other |
|
Derived under xeno-free conditions |
Unknown |
Derived under GMP? |
Unknown |
Available as clinical grade? |
Unknown |
Culture Conditions
Surface coating | Matrigel/Geltrex |
Feeder cells |
No |
Passage method |
Enzymatically
Accutase
|
O2 Concentration | 20 % |
CO2 Concentration | 5 % |
Medium |
mTeSR™ 1
|
Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
SOX2 |
Yes |
|
|
|||
NANOG |
Yes |
|
|
|||
POU5F1 (OCT-4) |
Yes |
|
|
|||
SOX2 |
Yes |
|
|
|||
NANOG |
Yes |
|
|
|||
POU5F1 (OCT-4) |
Yes |
|
|
Differentiation Potency
Microbiology / Virus Screening |
|
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
normal
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.